GOTHENBURG, Sweden, October 13, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) invites investors, shareholders and other stakeholders to […]
GOTHENBURG, Sweden, August 25, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
GOTHENBURG, Sweden, August 24, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical
GOTHENBURG, Sweden, July 8, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed
GOTHENBURG, Sweden, May 19, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
GOTHENBURG, Sweden, April 15, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority
GOTHENBURG, Sweden, April 10, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report
GOTHENBURG, Sweden, March 3, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate
GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s
GOTHENBURG, Sweden, February 18, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
